Pathological evaluation of the intrathalamic neurovirulence test of poliomyelitis vaccine in monkeys
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [8]
  • | | | |
  • Comments
    Abstract:

    Objective To investigate the pathological evaluation method of intrathalamic neurovirulence test of poliomyelitis vaccine in monkeys. Methods Two hundred and forty healthy rhesus monkeys age 1-3 years, body weight 1.7-4.5 kg, in 12 lots, were used in this study. The monkeys were injected with poliomyelitis vaccine into bilateral thalamus. The animals were sacrificed after observation for 21 days and specimens of the brain and spinal cord were collected. After dehydration, embedding and sectioning, HE and gallocyanin staining were used for pathological observation. The pathological changes were scored, and the severity of the pathological changes were determined by scoring. Results The sections were taken from bilateral cerebellum (needle tracts included), midbrain, pons, medulla oblongata, cervical enlargement and the lumbar enlargement. The pathological changes were evaluated referring to the hemisection scoring method of intraspinal neurovirulence test. Lesions on both sides of the brain stem, cervical enlargement and lumbar enlargement were scored, and the severity of the lesions at these three regions were determined according to the average score. The total incidence rate of specific neuronal pathological changes was 15%. The incidence rates of lesions caused by different types of vaccines were similar. Most of the lesions were minimal, and severe lesions were seen mainly in the type III vaccine tests. Conclusions In intrathalamic neurovirulence test, scoring of the lesions of nervous system by hemisections can objectively reflect the pathological changes in the nervous system. This method is simple and easy to apply, practical, and can facilitate the unification of diagnostic criteria. We would recommend this method to be used in pathological evaluation in intrathalamic neurovirulence test of poliomyelitis vaccine.

    Reference
    [1] Bencsk6 G, Ferenci T. Effective case/infection ratio of poliomyelitis in vaccinated populations[J]. Epidemiol Infect, 2016, Feb 2:1-10.
    [2] 谢忠平, 陈瀚博, 沈冬, 等. 口服脊髓灰质炎减毒活疫苗猴体神经毒力试验病理结果分析[J]. 中国生物制品学杂志, 2007, 20(3):206-208, 218.
    [3] 罗其胜, 王庆玲, 李艳梅, 等. 口服脊髓灰质炎活疫苗(OPV)猴体神经毒力试验国内外病理学检定结果分析[J]. 中国生物制品学杂志, 1998, 11(2):84-86
    [4] Nathanson N, Horn SD. Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988[J]. Vaccine, 1992, 10(7):469-474.
    [5] Contreras G, Fzlresz J, Karpinski K, et al. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine[J]. J Biol Stand, 1988, 16(3):195-205.
    [6] Sutter RW, Platt L, Mach O, et al. The new polio eradication end game:rationale and supporting evidence[J]. J Infect Dis, 2014, 210(S1):S434-438.
    [7] 杨建勇, 王红燕, 柯为华, 等. 口服脊髓灰质炎减毒活疫苗猴体神经毒力试验参考品合格标准的统计分析[J]. 微生物学免疫学进展, 2005, 33(4):7-12.
    [8] 罗其胜, 罗国祥, 陈淑范, 等. 口服脊髓灰质炎减毒活疫苗猴体神经毒力试验病理检定分析[J]. 生物制品学杂志, 1990, 3(2):73-77.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation
Share
Article Metrics
  • Abstract:1473
  • PDF: 1400
  • HTML: 0
  • Cited by: 0
History
  • Revised:April 10,2016
  • Online: November 02,2016
Article QR Code